Cutaneous side effects of new antitumor drugs: Clinical features and management;Kutane Nebenwirkungen von neuen medikamentösen Tumortherapien: Klinik und Management

Deutsches Arzteblatt International

Volumn 109, Issue 8, 2012, Pages 133-140

  Gutzmer, Ralf ^a   Wollenberg, Andreas ^b   Ugurel, Selma ^c   Homey, Bernhard ^d   Ganser, Arnold ^a   Kapp, Alexander ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVERSE DRUG REACTION; HUMAN; REVIEW; SKIN MANIFESTATION;

EID: 84903362244     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2012.0133     Document Type: Review

References (24)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
2. Potthoff K, Hofheinz R, Hassel JC, et al.: Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011; 22: 524-35.
3. Wollenberg A, Kroth J, Hauschild A, Dirschka T: Hautreaktionen unter EGFR-Inhibitoren - Klinik und Management. Dtsch Med Wochenschr 2010; 135: 149-54.
4. Gutzmer R, Becker JC, Enk A, et al.: Management kutaner Nebenwirkungen von FGFR-Inhibitoren: Empfehlungen eines deutschen Expertengremiums für den primär behandelnden Arzt. J Dtsch Dermatol Ges 2011; 9: 195-203.
5. Wollenberg A, Moosmann N, Klein E, Katzer K: A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 2008; 17: 790-2.
6. Eames T, Kroth J, Flaig MJ, Ruzicka T, Wollenberg A: Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy. Acta Derm Venereol 2010; 90: 202-3.
7. Eames T, Grabein B, Kroth J, Wollenberg A: Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol 2010; 24: 958-60.
8. Wollenberg A, Staehler M, Eames T: Kutane Nebenwirkungen der Multikinaseinhibitoren Sorafenib und Sunitinib. Hautarzt 2010; 61: 662-7.
9. Degen A, Alter M, Schenck F, et al.: Das Hand-Fuß-Syndrom als Nebenwirkung der medikamentösen Tumortherapie - Klassifikation und Management. J Dtsch Dermatol Ges 2010; 8: 652-61.
10. Farr KP, Safwat A: Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol 2011; 4: 229-35.
11. Kang YK, Lee SS, Yoon DH, et al.: Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 2010; 28: 3824-9.
12. Wolf SL, Qin R, Menon SP, et al.: Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 2010; 28: 5182-7.
13. Arnault JP, Wechsler J, Escudier B, et al.: Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009; 27: e59-e61.
14. Degen A, Satzger I, Voelker B, et al.: Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? Dermatology 2010; 221: 193-6.
15. Robert C, Arnault JP, Mateus C: RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011; 23: 177-82.
16. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
17. Kahler KC, Hauschild A: Hautveränderungen durch "targeted therapies" bei onkologischen Patienten: Kutane Nebenwirkungen zielgerichteter Therapie bei onkologischen Patienten. Hautarzt 2009; 60: 433-40.
18. Schad K, Baumann CK, Zipser MC, et al.: Mitogen-activated protein/ extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010; 16: 1058-64.
19. Trefzer U, Hofmann M, Sterry W: Kutane Nebenwirkungen klinisch relevanter Zytokintherapien. Dtsch Med Wochenschr 2003; 128: 1782-7.
20. Beck KE, Blansfield JA, Tran KQ, et al.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyteassociated antigen 4. J Clin Oncol 2006; 24: 2283-9.
21. Downey SG, Klapper JA, Smith FO, et al.: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681-8.
22. Hodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
23. Kahler KC, Hauschild A: Behandlung und Nebenwirkungs - manage ment des metastasierten Melanoms mit CTLA-4-Antikörpern. J Dtsch Dermatol Ges 2011; 9: 277-86.
24. Jaber SH, Cowen EW, Haworth LR, et al.: Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol 2006; 142: 166-72.